Ceribell files patent infringement complaints against Natus Medical

Medical technology firm Ceribell, Inc. (NASDAQ:CBLL) has filed patent infringement and unfair competition complaints against Natus Medical, seeking an import exclusion order and damages to protect its core EEG technology intellectual property. This aggressive legal move highlights Ceribell's focus on innovation, as the company, currently valued at $684 million, reported robust Q1 2025 revenue growth of 42% to $20.5 million, raised its full-year guidance to $83M-$87M, and boasts impressive 87% gross profit margins, despite anticipating a net loss this year. Additionally, Ceribell recently expanded its market with FDA clearance for a new pediatric seizure detection algorithm, while analysts like TD Cowen maintain a Buy rating, noting potential tailwinds from easing US-China trade tensions.

Analysis

Ceribell, Inc. (CBLL) has initiated aggressive legal action against Natus Medical, filing complaints with both the USITC and a U.S. District Court for patent infringement and unfair competition. This strategic move aims to protect its intellectual property in EEG technology through an exclusion order and damages, underscoring the company's commitment to defending its significant R&D investments. The litigation backdrop contrasts with a strong operational performance, as Ceribell reported a 42% year-over-year revenue increase to $20.5 million for Q1 2025 and an impressive 45% revenue growth over the last twelve months. Despite a net loss of $12.8 million in the quarter and analyst expectations for a net income decrease this year, the company's robust 87% gross profit margin indicates strong underlying product economics. Management's confidence is further signaled by the raised full-year revenue guidance to between $83 million and $87 million. Growth prospects are also supported by the recent FDA clearance for a new pediatric seizure detection algorithm, which expands its addressable market. Analyst sentiment remains positive, with TD Cowen maintaining a Buy rating and a $36 price target, citing potential margin benefits from easing trade tensions.

Key Decisions for Investors

• Investors should weigh Ceribell's high-growth profile, evidenced by 42% revenue growth and raised guidance, against its current lack of profitability and the inherent risks of a growth-stage company.
• The patent litigation against Natus is a critical factor to monitor, as a favorable outcome could secure Ceribell’s competitive moat, while a negative result could introduce significant costs and headwinds.
• Consider the recent FDA clearance for a pediatric algorithm as a key near-term growth catalyst and note that analyst ratings suggest potential upside, with easing US-China trade tensions identified as an additional tailwind for future profitability.